ANI Pharmaceuticals Files 8-K on Financials
Ticker: ANIP · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
ANI Pharma dropped an 8-K detailing financials and operations. Check it out.
AI Summary
ANI Pharmaceuticals, Inc. filed an 8-K on March 12, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company was formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.
Why It Matters
This 8-K filing provides investors with crucial updates on ANI Pharmaceuticals' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- ANI PHARMACEUTICALS, INC. (company) — Registrant
- BIOSANTE PHARMACEUTICALS INC (company) — Former name
- BEN ABRAHAM TECHNOLOGIES INC (company) — Former name
- March 12, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for ANI Pharmaceuticals?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as provide Regulation FD Disclosures and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on March 12, 2024.
What was ANI Pharmaceuticals, Inc. formerly known as?
ANI Pharmaceuticals, Inc. was formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.
Where is ANI Pharmaceuticals, Inc. headquartered?
ANI Pharmaceuticals, Inc. is headquartered at 210 Main Street West, Baudette, Minnesota 56623.
What is the SEC file number for ANI Pharmaceuticals, Inc.?
The SEC file number for ANI Pharmaceuticals, Inc. is 001-31812.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-12 07:07:04
Filing Documents
- ani-20240312.htm (8-K) — 29KB
- exhibit991-20240312.htm (EX-99.1) — 33KB
- exhibit991-20240312001.jpg (GRAPHIC) — 55KB
- exhibit991-20240312002.jpg (GRAPHIC) — 350KB
- exhibit991-20240312003.jpg (GRAPHIC) — 116KB
- exhibit991-20240312004.jpg (GRAPHIC) — 139KB
- exhibit991-20240312005.jpg (GRAPHIC) — 99KB
- exhibit991-20240312006.jpg (GRAPHIC) — 95KB
- exhibit991-20240312007.jpg (GRAPHIC) — 109KB
- exhibit991-20240312008.jpg (GRAPHIC) — 98KB
- exhibit991-20240312009.jpg (GRAPHIC) — 167KB
- exhibit991-20240312010.jpg (GRAPHIC) — 117KB
- exhibit991-20240312011.jpg (GRAPHIC) — 108KB
- exhibit991-20240312012.jpg (GRAPHIC) — 147KB
- exhibit991-20240312013.jpg (GRAPHIC) — 169KB
- exhibit991-20240312014.jpg (GRAPHIC) — 149KB
- exhibit991-20240312015.jpg (GRAPHIC) — 149KB
- exhibit991-20240312016.jpg (GRAPHIC) — 55KB
- exhibit991-20240312017.jpg (GRAPHIC) — 106KB
- exhibit991-20240312018.jpg (GRAPHIC) — 117KB
- 0001023024-24-000034.txt ( ) — 3427KB
- ani-20240312.xsd (EX-101.SCH) — 2KB
- ani-20240312_lab.xml (EX-101.LAB) — 21KB
- ani-20240312_pre.xml (EX-101.PRE) — 12KB
- ani-20240312_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On March 12, 2024, members of ANI Pharmaceuticals, Inc.'s (the "Company") senior management team met with investors at the Leerink Partners Global Biopharma Conference and provided an updated investor presentation. The Company will use the updated presentation in various meetings with investors from time to time. A copy of the presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
01
Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated March 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 12, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer